Gene therapy company Genprex Inc (NASDAQ:GNPX) Thursday announced the sale of 7,620,000 shares of common stock, par value USD0.001 per share, at-the-market offering price of USD1.05 per share, under purchase agreements with institutional investors.
There are no warrants in the offering, according to the company
Before deducting fees and other estimated offering expenses, the company expects gross proceeds from the offering of about USD8m.
Net proceeds may be used by the company to advance its lead clinical programmes in non-small cell lung cancer (NSCLC), working capital s well as for general corporate purposes.
AGP/Alliance Global Partners is acting as lead placement agent. Joseph Gunnar & Co LLC is acting as co-placement agent. The closing of the registered direct offering is expected to take place on or about 27 January 2020, subject to the satisfaction of customary conditions.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories